| 48056-6 |
Human bocavirus Ag |
PrThr |
XXX |
Pt |
Ord |
IF |
|
ACTIVE |
Human bocavirus Ag [Presence] in Specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Indeterminate Negative Positive |
|
|
|
|
|
MICRO |
|
48056-6 |
|
IF |
|
|
Both |
|
|
|
0 |
HBoV Ag Spec Ql IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; DFA; FA; Fluorescent antibody; Fluoresent; HBoV; HBoV Ag; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; Time Resolved Fluorescence; To be specified in another part of the message; TRF; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48057-4 |
Human bocavirus Ab.IgG |
PrThr |
XXX |
Pt |
Ord |
IA |
|
ACTIVE |
Human bocavirus IgG Ab [Presence] in Specimen by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
<4-fold rise >=4-fold rise Indeterminate No rise |
|
|
|
|
|
MICRO |
|
48057-4 |
|
IA |
|
|
Both |
|
|
|
0 |
HBoV IgG Spec Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; HBoV; HBoV Ab; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; SUDS; To be specified in another part of the message; Unspecified |
2.69 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48058-2 |
Fibrin D-dimer |
MCnc |
PPP |
Pt |
Qn |
IA.DDU |
|
ACTIVE |
Fibrin D-dimer [Mass/volume] in Platelet poor plasma by Immunoassay.DDU |
|
NAM |
DefinitionDescription |
|
|
ug/L DDU |
|
|
|
|
|
|
COAG |
|
48058-2 |
|
IA.DDU |
|
|
Both |
|
|
|
0 |
D Dimer PPP IA.DDU-mCnc |
|
|
|
N |
|
COAGULATION; D Dimer; Dextro; EIA; ELFA; ELISA; Enzyme immunoassay; Fragment D-dimer; Hematology; Heme; IAA; Level; Mass concentration; MEIA; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS; UniversalLabOrders |
2.79 |
2.21 |
|
|
|
|
|
|
|
ug/L{DDU} |
|
|
Release 2.79: METHOD_TYP: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; COMPONENT: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; Previous Releases: The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48059-0 |
Giardia lamblia+Cryptosporidium sp Ag |
PrThr |
Stool |
Pt |
Ord |
IA |
|
ACTIVE |
Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48059-0 |
|
IA |
|
|
Both |
|
|
|
0 |
G lamblia+Cryptosp Ag Stl Ql IA |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; Crypt; Crypto; Cryptosporidiosis; EIA; ELFA; ELISA; Enzyme immunoassay; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+Cryptosp; G lamblia+Cryptosp Ag; Giardiasis; IAA; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; spp; Stl; Stool = Fecal; SUDS |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4806-6 |
HLA-B13 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B13 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4806-6 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B13 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48060-8 |
Giardia lamblia+Cryptosporidium sp Ag |
PrThr |
Stool |
Pt |
Ord |
|
|
ACTIVE |
Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48060-8 |
|
|
|
|
Both |
|
|
|
0 |
G lamblia+Cryptosp Ag Stl Ql |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; Crypt; Crypto; Cryptosporidiosis; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+Cryptosp; G lamblia+Cryptosp Ag; Giardiasis; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; spp; Stl; Stool = Fecal; UniversalLabOrders |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48061-6 |
Giardia lamblia+Cryptosporidium sp Ag |
PrThr |
Stool |
Pt |
Ord |
IF |
|
ACTIVE |
Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48061-6 |
|
IF |
|
|
Both |
|
|
|
0 |
G lamblia+Cryptosp Ag Stl Ql IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Beaver fever; Bowel movement; Crypt; Crypto; Cryptosporidiosis; DFA; FA; Faecal; Faeces; Fecal; Feces; Fluorescent antibody; Fluoresent; G duodenalis; G intestinalis; G lamblia; G lamblia+Cryptosp; G lamblia+Cryptosp Ag; Giardiasis; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; spp; Stl; Stool = Fecal; Time Resolved Fluorescence; TRF |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48062-4 |
Giardia lamblia+Cryptosporidium parvum Ag |
PrThr |
Stool |
Pt |
Ord |
IF |
|
ACTIVE |
Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48062-4 |
|
IF |
|
|
Both |
|
|
|
0 |
G lamblia+C parvum Ag Stl Ql IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Beaver fever; Bowel movement; C parvum; Crypt; Crypto; Cryptosporidiosis; DFA; FA; Faecal; Faeces; Fecal; Feces; Fluorescent antibody; Fluoresent; G duodenalis; G intestinalis; G lamblia; G lamblia+C parvum; G lamblia+C parvum Ag; Giardiasis; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal; Time Resolved Fluorescence; TRF |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48063-2 |
Giardia lamblia+Cryptosporidium parvum Ag |
PrThr |
Stool |
Pt |
Ord |
IA |
|
ACTIVE |
Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48063-2 |
|
IA |
|
|
Both |
|
|
|
0 |
G lamblia+C parvum Ag Stl Ql IA |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; C parvum; Crypt; Crypto; Cryptosporidiosis; EIA; ELFA; ELISA; Enzyme immunoassay; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+C parvum; G lamblia+C parvum Ag; Giardiasis; IAA; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal; SUDS |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48064-0 |
Giardia lamblia+Cryptosporidium parvum Ag |
PrThr |
Stool |
Pt |
Ord |
|
|
ACTIVE |
Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48064-0 |
|
|
|
|
Both |
|
|
|
0 |
G lamblia+C parvum Ag Stl Ql |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; C parvum; Crypt; Crypto; Cryptosporidiosis; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+C parvum; G lamblia+C parvum Ag; Giardiasis; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48065-7 |
Fibrin D-dimer |
MCnc |
PPP |
Pt |
Qn |
FEU |
|
ACTIVE |
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma |
|
NAM |
DefinitionDescription |
|
|
ug/L FEU |
|
|
|
|
|
|
COAG |
|
48065-7 |
|
FEU |
|
|
Both |
|
|
|
0 |
D Dimer PPP FEU-mCnc |
|
|
|
N |
|
COAGULATION; D Dimer; Dextro; Fragment D-dimer; Hematology; Heme; Level; Mass concentration; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; UniversalLabOrders |
2.79 |
2.21 |
|
|
|
|
|
|
|
ng{FEU}/mL;mg{FEU}/L |
|
|
Release 2.79: COMPONENT: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; LONG_COMMON_NAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; SHORTNAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; |
161 |
| 48066-5 |
Fibrin D-dimer |
MCnc |
PPP |
Pt |
Qn |
DDU |
|
ACTIVE |
Fibrin D-dimer DDU [Mass/volume] in Platelet poor plasma |
|
NAM |
DefinitionDescription |
|
|
ug/L DDU |
|
|
|
|
|
|
COAG |
|
48066-5 |
|
DDU |
|
|
Both |
|
|
|
0 |
D Dimer PPP DDU-mCnc |
|
|
|
N |
|
COAGULATION; D Dimer; Dextro; Fragment D-dimer; Hematology; Heme; Level; Mass concentration; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; UniversalLabOrders |
2.79 |
2.21 |
|
|
|
|
|
|
|
ug/L{DDU} |
|
|
Release 2.79: COMPONENT: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; SHORTNAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; LONG_COMMON_NAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; |
0 |
| 48067-3 |
Fibrin D-dimer |
MCnc |
PPP |
Pt |
Qn |
IA.FEU |
|
ACTIVE |
Fibrin D-dimer [Mass/volume] in Platelet poor plasma by Immunoassay.FEU |
|
NAM |
DefinitionDescription |
|
|
ug/mL FEU |
|
|
|
|
|
|
COAG |
|
48067-3 |
|
IA.FEU |
|
|
Both |
|
|
|
0 |
D Dimer PPP IA.FEU-mCnc |
|
|
|
N |
|
COAGULATION; D Dimer; Dextro; EIA; ELFA; ELISA; Enzyme immunoassay; Fragment D-dimer; Hematology; Heme; IAA; Level; Mass concentration; MEIA; Plas; Platelet poor plasma; Point in time; QNT; Quan; Quant; Quantitative; Random; SUDS |
2.79 |
2.21 |
|
|
|
|
|
|
|
ug/mL{FEU} |
|
|
Release 2.79: METHOD_TYP: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; COMPONENT: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; LONG_COMMON_NAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; SHORTNAME: Change due to change in modeling heuristics as result of collaboration with SCT, and potential improvement in preparation for post-coordination; Previous Releases: The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48068-1 |
Heinz bodies |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Heinz bodies [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
48068-1 |
|
|
|
|
Observation |
|
|
|
0 |
Heinz Bod Bld Ql |
|
|
|
N |
|
Blood; bod; Body; HEMATOLOGY/CELL COUNTS; Ordinal; Point in time; PR; Precipitated Hemoglobin H; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48069-9 |
Spherocytes.micro |
PrThr |
Bld |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Spherocytes.micro [Presence] in Blood by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
48069-9 |
|
Microscopy.light |
|
|
Both |
|
|
|
0 |
Spherocytes.micro Bld Ql Smear |
|
|
|
N |
|
Blood; Hematology; HEMATOLOGY/CELL COUNTS; Heme; LM; Micro; Micros; Microscopic; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Sphero; Spherocyte; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4807-4 |
HLA-B13 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B13 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4807-4 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B13 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48070-7 |
Hepatitis B virus surface Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Hepatitis B virus surface IgG Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48070-7 |
|
IA |
|
|
Both |
|
|
|
0 |
HBV surface IgG Ser Ql IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; anti-HBsAg; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; HBs; HBsAB; HBV; HBV surface; Hep; Hep B; Hep Bs; Hepatis; Hepatit; Hepatology; HepB; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Liver; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; Surf |
2.56 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48071-5 |
Complement total hemolytic CH50 |
Titr |
Ser/Plas |
Pt |
SemiQn |
|
|
ACTIVE |
Complement total hemolytic CH50 [Titer] in Serum or Plasma |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
HEM/BC |
|
48071-5 |
|
|
|
|
Both |
|
|
|
0 |
CH50 Titr SerPl |
|
|
|
N |
|
Comp; Complement CH50; Complmt; Dilution factor; Dilution Factor (Titer); HEMATOLOGY/CELL COUNTS; Pl; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SmQn; SR; Titer; Titered; Titre; Tot; Total Hem Comp; Totl; Ttr |
2.75 |
2.21 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 48072-3 |
Synthetic glucocorticoid drug |
MCnc |
Unk sub |
Pt |
Qn |
|
|
ACTIVE |
Synthetic glucocorticoid drug [Mass/volume] in Unknown substance |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
48072-3 |
|
|
|
|
Both |
|
|
|
0 |
Synthetic Glucocorticoid Usub-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Unknown substance; Usub |
2.34 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 48073-1 |
Thyroxine binding globulin panel |
MCnc |
Ser/Plas |
Pt |
Qn |
Electrophoresis |
|
ACTIVE |
Thyroxine binding globulin panel [Mass/volume] - Serum or Plasma by Electrophoresis |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
48073-1 |
|
Electrophoresis |
|
|
Order |
|
|
|
0 |
T4BG Pnl SerPl Elph-mCnc |
|
|
|
N |
|
Bind; Chemistry; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; GLB; Glob; Glob%; Globul; Globulins; Level; Levothyroxine; Levo-thyroxine; L-thyroxine; Mass concentration; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; T4; T-4; T4BG; T4BG Pnl; TBG; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4 |
2.42 |
2.21 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 48074-9 |
Somatotropin^2.5H post dose arginine+insulin |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose arginine+insulin |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48074-9 |
|
|
|
|
Both |
|
|
|
0 |
GH 2.5h p Arg+Ins SerPl-aCnc |
|
|
|
N |
|
2.5h p Arg+Ins; After; Arbitrary concentration; Arg; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; NPH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
| 48075-6 |
Somatotropin^2.5H post dose betaxolol+glucagon |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose betaxolol+glucagon |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48075-6 |
|
|
|
|
Observation |
|
|
|
0 |
GH 2.5h p betaxolol+Gc SerPl-aCnc |
|
|
|
N |
|
2.5h p betaxolol; 2.5h p betaxolol+Gc; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
| 48076-4 |
Somatotropin^2.5H post dose glucagon |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Units/volume] in Serum or Plasma --2.5 hours post dose glucagon |
|
MIN |
DefinitionDescription |
|
|
mIU/L |
|
|
|
|
|
|
CHAL |
|
48076-4 |
|
|
|
|
Observation |
|
|
|
0 |
GH 2.5h p Gc SerPl-aCnc |
|
|
|
N |
|
2.5h p Gc; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGF; HGH; Human growth hormone; Hyperglycemic factor; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
|
0 |
| 48077-2 |
Thyrotropin^2.5H post dose luteinizing releasing hormone IV |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thyrotropin [Units/volume] in Serum or Plasma --2.5 hours post dose luteinizing releasing hormone IV |
|
MIN |
DefinitionDescription |
|
|
mIU/L;mcU/mL |
|
|
|
|
|
|
CHAL |
|
48077-2 |
|
|
|
|
Observation |
|
|
|
0 |
TSH 2.5h p LRH IV SerPl-aCnc |
|
|
|
N |
|
2.5h p LRH IV; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Horm; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Thyroid stimulating hormone; Thyrotropic hormone; TSH |
2.7 |
2.21 |
|
|
|
|
|
|
|
m[IU]/L |
|
|
Release 2.69: COMPONENT: Corrected "lutenizing" to "luteinizing"; |
0 |
| 48078-0 |
3,6-Epoxydecanedioate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
3,6-Epoxydecanedioate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48078-0 |
|
|
|
|
Both |
|
|
|
0 |
3,6-epoxydecanedioate/Creat Ur-sRto |
|
|
|
N |
|
3,6-epoxydecanedioic acid; Chemistry; CR; Crea; Creat; III; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
